Gide advises the banking syndicate on the €60 million financing by Sensorion

Gide has advised the banking syndicate composed of Leerink Partners, Stifel and Baird on the €60 million financing by Sensorion, including a €20 million strategic investment by Sanofi. The transaction was carried out through the issuance of new shares to specialist investors. Sensorion’s ordinary shares are listed for trading on Euronext Growth in Paris.

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. This fundraising will principally finance Sensorion’s R&D activities related to its gene therapy programs, SENS-501 and SENS-601 (GJB2-GT), evenly, as well as for its other R&D and corporate overhead expenses.

Gide had also advised the banks on Sensorion’s capital increase in 2024.

The Gide team was led by partner Arnaud Duhamel and comprised counsel Aude-Laurène Dourdain and associates Yasmine Tanji and Marie des Neiges Paupe.